---

Background

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by the loss of motor neurons, leading to muscle weakness, paralysis, and ultimately respiratory failure. While induced pluripotent stem cell (iPSC)-derived motor neurons have emerged as promising human disease models, reproducing the biology of sporadic ALS, which accounts for approximately 90% of cases, has remained a major challenge. Existing models often fail to consistently capture disease-associated phenotypes or provide the reproducibility required for large-scale therapeutic screening.

Biolaminin® contribution

To establish a robust and scalable motor neuron differentiation and phenotyping platform, the researchers optimized an existing differentiation protocol. As part of the workflow, motor neuron progenitors were replated onto culture plates coated with Biolaminin 521 before terminal differentiation and long-term phenotypic screening. The optimized platform consistently generated highly enriched motor neuron cultures that supported automated longitudinal imaging, large-scale phenotypic analysis, and drug screening across a diverse patient-derived iPSC library.

Results

Using this platform, the researchers generated one of the largest reported iPSC libraries for sporadic ALS, comprising motor neurons derived from 100 patients alongside healthy controls. Patient-derived motor neurons recapitulated key features of sporadic ALS, including reduced survival, accelerated neurite degeneration, and disease-associated transcriptional changes that correlated with patient outcomes. The platform was subsequently used to screen 107 compounds previously evaluated in ALS clinical trials. While most compounds failed to improve motor neuron survival, consistent with the limited success of previous clinical trials, riluzole, baricitinib, and memantine demonstrated therapeutic potential. Further testing identified combinations of these compounds, particularly the tripe combination of riluzole, baricitinib, and memantine, as providing the greatest improvement in motor neuron survival across patient-derived cultures.

Why it matters

Developing effective therapies for sporadic ALS depends on disease models that faithfully reproduce human pathology while supporting large-scale drug discovery. In this study, the researchers established an optimized motor neuron differentiation and phenotyping platform incorporating Biolaminin 521 that supported large-scale phenotypic screening across one of the largest patient-derived sporadic ALS iPSC libraries reported to date. The study demonstrates how robust, defined stem cell culture workflows can provide a valuable foundation for disease modeling, preclinical therapeutic evaluation, and future drug discovery in ALS.

Cited study: Bye CR, Qian E, Lim K, et al. Large-scale drug screening in iPSC-derived motor neurons from sporadic ALS patients identifies a potential combinatorial therapy. Nature Neuroscience. 2026. DOI: 10.1038/s41593-025-02118-7

---